Formoterol Turbuhaler® twice daily is more cost-effective than salmeterol twice daily or as-needed salbutamol

F. E. Berggren, K. Svensson, M. S. Rolnick, S. Mintz, On behalf of the Canadian Investigators (Lund, Sweden; Mississauga, Toronto, Canada)

Source: Annual Congress 2001 - Asthma and COPD management in primary care
Session: Asthma and COPD management in primary care
Session type: Poster Discussion
Number: 2199
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. E. Berggren, K. Svensson, M. S. Rolnick, S. Mintz, On behalf of the Canadian Investigators (Lund, Sweden; Mississauga, Toronto, Canada). Formoterol Turbuhaler® twice daily is more cost-effective than salmeterol twice daily or as-needed salbutamol. Eur Respir J 2001; 16: Suppl. 31, 2199

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001

Sustained FEV1 increases in COPD patients induced by salmeterol 50 mcg twice daily via the diskus inhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 240s
Year: 2002

Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Budesonide 800 μg/day via Easyhaler® is as safe and effective as the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient
Source: Annual Congress 2010 - Management of airway disease
Year: 2010